CONTENTS OF ADIPONETIN, VISFATIN, TOLL-LIKE RECEPTOR-4 AND ARGINASE-II IN METABOLICLY COMPROMISED PATIENTS WITH ARTERIAL HYPERTENSION

Authors

DOI:

https://doi.org/10.32782/2786-9067-2024-27-12

Keywords:

arterial hypertension, adiponectin, visfatin, TLR4, arginase-II

Abstract

Introduction. Hypertension is a major risk factor for cardiovascular events in overweight/ obese patients. Adipocytokine imbalance, activation of the immune system, and inflammation occur in hypertension, the role of which in the pathogenesis has not yet been sufficiently investigated. The purpose of the work: to estimate the content of adiponectin, visfatin, Toll-like receptor-4 and arginase- II in metabolically compromised cases with arterial hypertension. Materials and methods. 76 overweight/obese patients with a diagnosis of arterial hypertension and receiving antihypertensive drugs were examined in a randomized manner. Patients were divided into two groups: 1st group - 38 patients who reached the target BP, 2nd group - 38 people who did not reach the target BP. All study participants had their medical and life histories collected, underwent a general physical examination with blood pressure measurement and BMI calculation, general clinical (total blood count, coagulogram, biochemical blood analysis, lipidogram) and immunoenzyme studies to determine the concentrations of adiponectin, visfatin, TLR4, and arginase-II in blood serum and lymphocytes using ELISA Kit reagents. The results. Patients who reached the target blood pressure had reliably higher concentrations of serum adiponectin on the background of significantly lower levels of visfatin, TLR4 and arginase-II. Accordingly, reliably higher levels of visfatin, TLR4, arginase-II in serum were observed in patients who did not reach the target blood pressure level, against the background of reliably reduced levels of adiponectin in serum. On the other hand, in peripheral blood lymphocytes, no credibly difference was determined between adiponectin, visfatin, TLR4 and arginase-II indicators when comparing between groups. Additionally, inverse correlations were found between adiponectin and AST, creatinine and urea; high levels of visfatin were directly associated with BMI, SBP, LDL-C, TG, AST, fibrinogen and MNV; direct correlations of TLR4 with BMI, blood leukocytes, PF, AST, creatinine were determined against the background of an inverse correlation with HDL-C; high levels of arginase-II were directly associated with SBP, BMI, ALT, AST, LDL-C, TG. Conclusions. In metabolically compromised patients with hypertension who did not reach the target blood pressure during antihypertensive therapy, according to current recommendations, high levels of blood pressure are associated with a low concentration of the anti-inflammatory and anti-atherosclerotic adipokine – adiponectin, against the background of high concentrations of pro-inflammatory factors – visfatin, TLR4 and arginase-II. Furthermore, correlations between the indicators of adiponectin, visfatin, TLR4, arginase-II and the results of age-related, physical and laboratory examinations were determined, which confirm the participation of the above-mentioned factors in the pathogenesis of hypertension in metabolically compromised patients.

References

Abdalla M.M.I. Role of visfatin in obesity-induced insulin resistance. World journal of clinical cases. 2022. Vol. 10, № 30. Р. 10840–10851. https://doi.org/10.12998/wjcc.v10.i30.10840.

Cai M., Zhao D., Han X., Han S., Zhang W., Zang Z., Gai C., Rong R., Gao T. The role of perivascular adipose tissue-secreted adipocytokines in cardiovascular disease. Frontiers in immunology. 2023. Vol. 14. 1271051. DOI: https://doi.org/10.3389/fimmu.2023.1271051.

Clemente-Suárez V.J., Redondo-Flórez L., Beltrán-Velasco A.I., Martín-Rodríguez A., Martínez-Guardado I., Navarro-Jiménez E., Laborde-Cárdenas C.C., Tornero-Aguilera J.F. The Role of Adipokines in Health and Disease. Biomedicines. 2023. Vol. 11, № 5. 1290. DOI: https://doi.org/10.3390/biomedicines11051290.

Dakroub A., Nasser S., Younis N., Bhagani H., Al-Dhaheri Y., Pintus G., Eid A.A., El-Yazbi A.F., Eid A.H. Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders. Cells. 2020. Vol. 9, № 11. 2444. DOI: https://doi.org/10.3390/cells9112444.

Erten M. Visfatin as a Promising Marker of Cardiometabolic Risk. Acta Cardiologica Sinica. 2021. Vol. 37, № 5. Р. 464–472. https://doi.org/10.6515/ACS.202109_37(5).20210323B.

Feijóo-Bandín S., Aragón-Herrera A., Moraña-Fernández S., Anido-Varela L., Tarazón E., Roselló-Lletí E., Portolés M., Moscoso I., Gualillo O., González-Juanatey J.R., Lago F. Adipokines and Inflammation: Focus on Cardiovascular Diseases. International journal of molecular sciences. 2023. Vol. 21, № 20. 7711. DOI: https://doi.org/10.3390/ijms21207711.

Janaszak-Jasiecka A., Płoska A., Wierońska J.M., Dobrucki L.W., Kalinowski L. Endothelial dysfunction due to eNOS uncoupling: molecular mechanisms as potential therapeutic targets. Cellular & molecular biology letters. 2023. Vol. 28, № 1. 21. DOI: https://doi.org/10.1186/s11658-023-00423-2.

Kim A.Y., Park Y.J., Pan X., Shin K.C., Kwak S.H., Bassas A.F., Sallam R.M., Park K.S.,

Alfadda A.A., Xu A., Kim J.B. Obesity-induced DNA hypermethylation of the adiponectin gene mediates insulin resistance. Nature communications. 2015. Vol. 6. 7585. https://doi.org/10.1038/ncomms8585.

Lazaridis A., Gavriilaki E., Douma S., Gkaliagkousi E. Toll-Like Receptors in the Pathogenesis of Essential Hypertension. A Forthcoming Immune-Driven Theory in Full Effect. International journal of molecular sciences. 2021. Vol. 22, № 7. 3451. DOI: https://doi.org/10.3390/ijms22073451.

Li Z., Wang L., Ren Y., Huang Y., Liu W., Lv Z., Qian L., Yu Y., Xiong Y. Arginase: shedding light on the mechanisms and opportunities in cardiovascular diseases. Cell death discovery. 2022. Vol. 8, № 1. 413. DOI: https://doi.org/10.1038/s41420-022-01200-4.

Maksymets T.A., Sklyarova H.E. The relationship between insulin resistance, adipokines, lipids and low-grade inflammation in patients by cardiovascular disease treated with statins. Medical science of Ukraine. 2023. Vol.19, № 3. Р. 23–30. DOI: https://doi.org/10.32345/2664-4738.3.2023.04.

Maximus P.S., Al Achkar Z., Hamid P.F., Hasnain S.S., Peralta C.A. Adipocytokines: Are they the Theory of Everything? Cytokine. 2020. Vol. 133. 155144. DOI: https://doi.org/10.1016/j.cyto.2020.155144.

Navaneethabalakrishnan S., Smith H.L., Arenaz C.M., Goodlett B.L., McDermott J.G., Mitchell B.M. Update on Immune Mechanisms in Hypertension. American journal of hypertension. 2022. Vol. 35, № 10. Р. 842–851. DOI: https://doi.org/10.1093/ajh/hpac077.

Nunes K.P., Bomfim G.F., Toque H.A., Szasz T., Clinton Webb R. Toll-like receptor 4 (TLR4) impairs nitric oxide contributing to Angiotensin II-induced cavernosal dysfunction. Life sciences. 2017. Vol. 191. P. 219–226. DOI: https://doi.org/10.1016/j.lfs.2017.10.014.

Parimelazhagan R., Umapathy D., Sivakamasundari I.R., Sethupathy S., Ali D., Kunka Mohanram R., Namasivayan N. Association between Tumor Prognosis Marker Visfatin and Proinflammatory Cytokines in Hypertensive Patients. BioMed research international. 2021. 8568926. DOI: https://doi.org/10.1155/2021/8568926.

Romacho T., Valencia I., Ramos-González M., Vallejo S., López-Esteban M., Lorenzo O., Cannata P., Romero A., San Hipólito-Luengo A., Gómez-Cerezo J.F., Peiró C., Sánchez-Ferrer C.F. Visfatin/eNampt induces endothelial dysfunction in vivo: a role for Toll-Like Receptor 4 and NLRP3 inflammasome. Scientific reports. 2020. Vol. 10, № 1. 5386. DOI: https://doi.org/10.1038/s41598-020-62190-w.

Rotkegel S., Chudek J., Spiechowicz-Zaton U., Ficek R., Adamczak M., Wiecek A. The effect of sodium restricted diet on plasma visfatin levels in hypertensive patients with visceral obesity. Kidney & blood pressure research. 2013. Vol. 37, № 2-3. Р. 124–131. DOI: https://doi.org/10.1159/000350066.

S. Clemente G., van Waarde A., F. Antunes I., Dömling A., H. Elsinga P. Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective. Int. J. Mol. Sci. 2020. Vol. 21. 5291. DOI: https://doi.org/10.3390/ijms21155291.

Sklyarova O.Y., Mahiiovych S.R., Denysenko N.V., Kobylinska L.I., Sklyarov Y.Y. The level of nitric oxide and arginase activity in patients with arterial hypertension and diabetes mellitus during COVID-19. Ukr. Biochem. J. 2022. Vol. 94, № 5. P. 18-27. doi: https://doi.org/10.15407/ubj94.05.018.

Sowka A., Dobrzyn P. Role of Perivascular Adipose Tissue-Derived Adiponectin in Vascular Homeostasis. Cells. 2021. Vol. 10, № 6. 1485. https://doi.org/10.3390/cells10061485.

Tasneem S., Liu B., Li B., Choudhary M.I., Wang W. Molecular pharmacology of inflammation: Medicinal plants as anti-inflammatory agents. Pharmacological research. 2019. Vol. 139. P. 126–140. DOI: https://doi.org/10.1016/j.phrs.2018.11.001.

Vasamsetti S.B., Natarajan N., Sadaf S., Florentin J., Dutta, P. Regulation of cardiovascular health and disease by visceral adipose tissue-derived metabolic hormones. The Journal of physiology. 2023. Vol. 601, № 11. Р. 2099–2120. DOI: https://doi.org/10.1113/JP282728.

Wang X., Zhang S., Li Z. Adipokines in glucose and lipid metabolism. Adipocyte. 2023. Vol. 12, №1. 2202976. DOI: https://doi.org/10.1080/21623945.2023.2202976.

Williams B., Mancia G., Spiering W. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. J. Hypertens. 2018. Vol. 36. P. 1953–2041. DOI: https://doi.org/10.1097/HJH.0000000000001940.

Wu O., Lu X., Leng J. et al. Reevaluating Adiponectin’s impact on obesity hypertension: a Chinese case-control study. BMC Cardiovasc Disord. 2024. Vol. 24. 208. DOI: https://doi.org/10.1186/s12872-024-03865-417.

Yu P.L., Wang C., Li W., Zhang F.X. Visfatin Level and The Risk of Hypertension and Cerebrovascular Accident: A Systematic Review and Meta-Analysis. Hormone and metabolic research. 2019. Vol. 51, № 4. Р. 220–229. https://doi.org/10.1055/a-0867-1333.

Zheng M., Lu N., Ren M., Chen H. Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction. BMC cardiovascular disorders. 2020. Vol. 20, № 1. 271. DOI: https://doi.org/10.1186/s12872-020-01549-3.

Published

2024-09-10